The absolute importance of Dr. Clay Siegall in cancer research can’t be put into words. The importance can’t even be questioned. This man has years and years of experience, especially when dealing with the topic of cancer. Organizations such as Bristol Myers Squibb, the National Institute of Health and the National Cancer Society have all worked with Dr. Siegall throughout the years. One of his very first jobs was for being a senior researcher at Bristol Myers Squibb, but as of today, he is the captain of a humungous ship that’s known as Seattle Genetics. The Bothell, Washington-based company has a specialty for producing and for commercializing top-rated antibodies. These antibodies are very advanced in their course of actions, and they’re known as targeted-cancer therapies.
Seattle Genetics has risen onto the scene in flying colors. Though it struggled a bit in the first few years, it is now a game-changer for cancer patients worldwide. The company has copious amounts of drugs in its infamous pipeline, and it is constantly spending millions of dollars on perfecting the drugs to efficiently fight cancer. Yes, that was a mouthful to say, but it’s the truth. Seattle Genetics is aspiring to graduate from being just a drug developer. The company is aspiring to reach the absolute highest position by becoming a pharmaceutical-giant that holds all of its rights. Dr. Siegall has spent a considerable amount of time studying this process, and he has taken steps to personify this dream.
This company has a net worth of $10 billion. Its progress comes from multiple pathways, which includes drug development, the selling of its proprietary drugs, production partnerships and the licensing of its technologies. Dr. Siegall has implemented many of Genentech’s business moves as he has thoroughly studied the founder of this mega-giant company. All in all, the mortality rate is decreasing and Dr. Clay Siegall plays a huge role in this progressive transitioning.